Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.

@article{Krentz2018PatientPO,
  title={Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.},
  author={Hartmut B Krentz and Sandra Kaye Campbell and Victoria C Gill and Michael J. Gill},
  journal={HIV medicine},
  year={2018},
  volume={19 4},
  pages={290-298}
}
OBJECTIVES The incremental costs of expanding antiretroviral (ARV) drug treatment to all HIV-infected patients are substantial, so cost-saving initiatives are important. Our objectives were to determine the acceptability and financial impact of de-simplifying (i.e. switching) more expensive single-tablet formulations (STFs) to less expensive generic-based… CONTINUE READING